BioSpace News Archive

Hemanext Inc. today announced that it has entered into distribution agreements with two leading medical device distributors in the Nordics and Italy, bolstering its sales capabilities across key European markets and strengthening its relationships with key blood centers and clinicians in each region.

Researcher from Cytimmune Sciences, a clinical-stage biotechnology company, presented new data on the company’s novel cancer nanomedicines at the Cytokine Drug Development Conference held in Boston, Massachusetts on July 26-28.

The National Comprehensive Cancer Network (NCCN) recently announced new guidelines that recommend testing for all patients diagnosed with colon cancer.

IIOT-OXYS, Inc. announces the availability of a new interview with its CEO, Cliff Emmons, with SmallCapVoice.com Inc.

Jaguar Health today announced that its Orphan Drug Designation (ODD) application for crofelemer submitted to the U.S. Food and Drug Administration for a rare congenital diarrheal disorder called microvillus inclusion disease (MVID) has been accepted by the FDA for review.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Carmustine to its line of chemotherapy drugs.

CRIO, a Boston-based healthcare technology firm streamlining clinical trials for sponsors, sites, and patients, has been selected as the eSource vendor for a 200 patient MDD trial.

Satio and INTACT Solutions have entered into an agreement to establish a collaborative framework in order to partner on research, development, manufacture, and deployment of next generation health technologies with the goal of offering alternative solutions to traditional needles with SatioRx™ intradermal patches for the Member States of the African Union and beyond.

Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced NSCLC patients who are resistant to first-line EGFR kinase inhibitor therapies. In this pivotal study conducted in China, matured data of 209 response evaluable NSCLC patients were assessed by an IRC. The overall response rate (ORR) as confirmed by the IRC was 56.5% (118/209) and among them, 11 patients had complete responses (CR) with a CR rate of

Global health services company Cigna Corporation (NYSE: CI) announced today that David Cordani, chairman and chief executive officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022 in New York, NY.